India has rejected a patent application for Abbott’s HIV/AIDS treatment Kaletra, reigniting a debate over the country’s patent rules.

The Economist’s Intelligence Unit reports: Tahir Amin, co-founder and director of the Initiative for Medicines, Access & Knowledge, whose group filed an opposition to the Kaletra application in August 2008, said that Abbott has been using the patent system to enable it to charge prices that put its AIDS medicines out of the reach of those who need them most.